Aldosterone and the autocrine modulation of potassium currents and oxidative stress in the diabetic rat heart

British Journal of Pharmacology

Volumn 154, Issue 3, 2008, Pages 675-687

  Shimoni, Y ^a   Chen, K ^a   Emmett, T ^a   Kargacin, G ^a  

^a UNIVERSITY OF CALGARY   (Canada)

Author keywords

Aldosterone; Aldosterone synthase; Cardiac potassium currents; Diabetes; Gender; Oxidative stress

Indexed keywords

ALDOSTERONE; ANGIOTENSIN II; FAD 286; HYDROETHIDINE; OXYGENASE INHIBITOR; QUINAPRIL; SPIRONOLACTONE; STREPTOZOCIN; SUPEROXIDE;

ACTION POTENTIAL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOCRINE EFFECT; CONTROLLED STUDY; DIABETES MELLITUS; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLUORESCENCE; HEART MUSCLE CELL; HEART VENTRICLE; HORMONE BLOOD LEVEL; MALE; NONHUMAN; ORCHIECTOMY; OVARIECTOMY; OXIDATIVE STRESS; POTASSIUM CURRENT; PRIORITY JOURNAL; PROTEIN FUNCTION; RAT; SEX DIFFERENCE; VOLTAGE CLAMP;

ALDOSTERONE; ANGIOTENSIN II; ANIMALS; AUTOCRINE COMMUNICATION; DIABETES MELLITUS, EXPERIMENTAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; ETHIDIUM; FEMALE; MALE; MYOCYTES, CARDIAC; OXIDATIVE STRESS; PATCH-CLAMP TECHNIQUES; POTASSIUM; POTASSIUM CHANNELS; RATS; RATS, SPRAGUE-DAWLEY; SEX FACTORS; SUPEROXIDES;

EID: 44349085313     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/bjp.2008.114     Document Type: Article

References (71)

1. Abo K, Ishida Y, Yoshida R, Hozumi T, Ueno H, Shiotani H et al. (1996). Torsade de Pointes in NIDDM with long QT intervals. Diabetes Care 9: 1010.
2. Bell DSH (2003). Diabetic cardiomyopathy. Diabetes Care 26: 2949-2951.
3. + current density in rat ventricular myocytes. J Physiol 537: 151-160.
4. Bos R, Mougenot N, Findji L, Mediani O, Vanhoutte PM, Lechat P (2005). Inhibition of catecholamine-induced cardiac fibrosis by an aldosterone antagonist. J Cardiovasc Pharmacol 45: 8-13.
5. Brouillette J, Trepanier-Boulay V, Fiset C (2003). Effect of androgen deficiency on mouse ventricular repolarization. J Physiol 546: 403-413.
6. Casal AJ, Silvestre JS, Delcayre C, Capponi AM (2003). Expression and modulation of steroidogenic acute regulatory protein messenger ribonucleic acid in rat cardiocytes and after myocardial infarction. Endocrinology 144: 1861-1868.
7. Chai W, Garrelds IM, de Vries R, Danser AHJ (2006). Cardioprotective effects of eplerenone in the rat heart. Hypertension 47: 665-670.
8. Daleau P, Turgeon J (1994). Angiotensin II modulates the delayed rectifier potassium current of guinea pig ventricular myocytes. Pflugers Arch 427: 553-555.
9. D'Amico M, Marfella R, Nappo F, Di Fillipo C, De Angelis L, Berrino L et al. (2001). High glucose induces ventricular instability and increases vasomotor tone in rats. Diabetologia 44: 464-470.
10. Delcayre C, Silvestre JS, Garnier A, Oubenaissa A, Cailmail S, Tatara E et al. (2000). Cardiac aldosterone production and ventricular remodeling. Kidney Int 57: 1346-1351.
11. El-Atat FA, McFarlane SI, Sowers JR, Bigger JT (2004). Sudden cardiac death in patients with diabetes. Curr Diab Rep 4: 187-193.
12. Emmett M (2006). Cardiac aldosterone synthesis? Am J Cardiol 97: 1107-1108.
13. Ewing DJ, Boland O, Neilson JMM, Cho CG, Clarke BF (1991). Autonomic neuropathy, QT interval lengthening, and unexpected deaths in male diabetic patients. Diabetologia 34: 182-185.
14. Fiebeler A, Nussberger J, Shagdarsuren E, Rong S, Hilfenhaus G, Al-Saadi N et al. (2005). Aldosterone synthase inhibitor ameliorates angiotensin II-induced organ damage. Circulation 111: 3087-3094.
15. Fiordaliso F, Li B, Latini R, Sonnenblick EH, Anversa P, Leri A et al. (2000). Myocyte death in streptozotocin-induced diabetes in rats is angiotensin II-dependent. Lab Invest 80: 513-527.
16. Fischer M, Baessler A, Schunkert H (2002). Renin angiotensin system and gender differences in the cardiovascular system. Cardiovasc Res 53: 672-677.
17. Fischer R, Dechend R, Gapelyuk A, Shagdarsuren E, Gruner K, Gruner A et al. (2007). Angiotensin II-induced sudden arrhythmic death and electrical remodeling. Am J Physiol 293: H1242-H1253.
18. Fonarow GC (2005). An approach to heart failure and diabetes. Am J Cardiol 96 (Suppl 1): 47-52.
19. Fraccarollo D, Galuppo P, Schmidt I, Ertl G, Bauersachs J (2005). Additive amelioration of left ventricular remodeling and molecular alterations by combined aldosterone and angiotensin receptor blockade after myocardial infarction. Cardiovasc Res 67: 97-105.
20. Frustaci A, Kajstura J, Chimenti C, Jakoniuk I, Leri A, Maseri A et al. (2000). Myocardial cell death in human diabetes. Circ Res 87: 1123-1132.
21. Funder JW (2004). Is aldosterone bad for the heart? Trends Endocrinol Metab 15: 139-142.
22. Gomez-Sanchez EP, Ahmad N, Romero DG, Gomez-Sanchez CE (2004). Origin of aldosterone in the heart. Endocrinol 145: 4796-4802.
23. Guzik TJ, Mussa S, Gastaldi D, Sadowski J, Ratnatunga C, Pillai R et al. (2002). Mechanisms of increased vascular superoxide production in human diabetes mellitus. Circulation 105: 1656-1662.
24. Hollenberg NK, Stevanovic R, Agarwal A, Lansang MC, Price DA, Laffel LMB et al. (2004). Plasma aldosterone concentration in the patient with diabetes mellitus. Kidney Int 65: 1435-1439.
25. Jefic D, Mohiuddin N, Alsabbagh R, Fadanelli M, Steigerwalt S (2006). The prevalence of primary aldosteronism in diabetic patients. J Clin Hypertens 8: 253-256.
26. Jorde UP, Vittorio T, Katz SD, Colombo PC, Latif F, Le Jemtel TH (2002). Elevated plasma aldosterone levels despite complete inhibition of the vascular angiotensin-converting enzyme in chronic heart failure. Circulation 106: 1055.
27. Katada J, Meguro T, Saito H, Ohashi A, Anzai T, Ogawa S et al. (2005). Persistent cardiac aldosterone synthesis in angiotensin II type 1A receptor-knockout mice after myocardial infarction. Circulation 111: 2157-2164.
28. Lim HS, MacFayden RJ, Lip GYH (2004). Diabetes mellitus, the renin-angiotensin-aldosterone system, and the heart. Arch Intern Med 164: 1737-1748.
29. Mann JF, Yi QL, Sleight P, Dagenais GR, Gerstein HC, Lonn EM et al. (2005). Serum potassium, cardiovascular risk, and effects of an ACE inhibitor: results of the HOPE study. Clin Nephrol 63: 181-187.
30. Marney AM, Brown NJ (2007). Aldosterone and end-organ damage. Clin Sci (Lond) 113: 267-268.
31. Matsumura K, Fujii K, Kansui Y, Arima H, Iida M (2005). Prolongation of the QT interval in primary aldosterone. Clin Exp Pharmacol Physiol 32: 66-69.
32. McFarlane SI, Sowers JR (2003). Aldosterone function in diabetes mellitus: effects on cardiovascular and renal disease. J Clin Endocrinol Metab 88: 516-523.
33. Menard J, Gonzalez MF, Guyene TT, Bissery A (2006). Investigations of aldosterone-synthase inhibition in rats. J Hypertens 24: 1147-1155.
34. Michel F, Ambroisine ML, Duriez M, Delcayre C, Levy BI, Silvestre JS (2004). Aldosterone enhances ischemia-induced neovascularization through angiotensin II-dependent pathway. Circulation 109: 1933-1937.
35. Mizuno Y, Yasue H, Yoshimura M, Harada E, Fujii H, Nakamura S et al. (2005). Adrenocorticotrophic hormone is produced in the ventricle of patients with essential hypertension. J Hypertens 23: 411-416.
36. Mizuno Y, Yoshimura M, Yasue H, Sakamoto T, Ogawa H, Kugiyama K et al. (2001). Aldosterone production is activated in failing ventricle in humans. Circulation 103: 72-77.
37. Mooradian AD (2000). Cardiovascular disease in type 2 diabetes mellitus. Arch Int Med 163: 33-40.
38. Nakayama T, Izumi Y, Soma M, Kanmatsue K (1998). Adrenal renin-angiotensin-aldosterone system in streptozotocin-diabetic rats. Horm Metab Res 30: 12-15.
39. + channel diversity in the mammalian myocardium. J Physiol 525: 285-298.
40. Nikpoor D, Duan QL, Rouleau GA (2005). Acute adverse reactions associated with angiotensin-converting-enzyme inhibitors; genetic factors and therapeutic implications. Expert Opin Pharmacother 6: 1851-1856.
41. Ohtani T, Ohta M, Yamamoto K, Mano T, Sakata Y, Nishio M et al. (2007). Elevated cardiac tissue level of aldosterone and mineralocorticoid receptor in diastolic heart failure: beneficial effects of mineralocorticoid receptor blocker. Am J Physiol 292: R946-R954.
42. Ouvrard-Pascaud A, Sainte-Marie Y, Benitah JP, Perrier R, Soukaseum C, Cat AND et al. (2005). Conditional mineralocorticoid receptor expression in the heart leads to life-threatening arrhythmias. Circulation 111: 3025-3033.
43. Perrier E, Kerfant BG, Lalevee N, Bideaux P, Rossier MF, Richard S et al. (2004). Mineralocorticoid receptor antagonism prevents the electrical remodeling that precedes cellular hypertrophy after myocardial infarction. Circulation 110: 776-783.
44. Pitt B, Remme WJ, Zannad F, Neaton J, Martinez F, Roniker B et al. (2003). Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348: 1309-1321.
45. Poirier P, Despres JP, Bertrand OF (2006). Identifying which patients with diabetes should be tested for the presence of coronary artery disease - the importance of baseline electrocardiogram and exercise testing. Can J Cardiol 22 (Suppl A): 9-15.
46. Rana BS, Lim PO, Naas AA, Ogston SA, Newton RW, Jung RT et al. (2005). QT interval abnormalities are often present at diagnosis in diabetes and are better predictors of cardiac death than ankle brachial pressure index and autonomic function tests. Heart 91: 44-50.
47. Reckelhoff JF, Yanes LL, Iliescu R, Fortepiani LA, Granger JP (2005). Testosterone supplementation in aging men and women: possible impact on cardiovascular-renal disease. Am J Physiol 289: F941-F948.
48. Rossi GP, Sacchetto A, Cesari M, Pessina AC (1999). Interactions between endothelin-1 and the renin-angiotensin-aldosterone system. Cardiovasc Res 43: 300-307.
49. c interval predicts mortality in patients with type 1 diabetes mellitus. Diabet Med 18: 199-205.
50. Sato A, Funder JW (1996). High glucose stimulates aldosterone-induced hypertrophy via type I mineralocorticoid receptors in neonatal rat cardiomyocytes. Endocrinology 137: 4145-4153.
51. Severson DL (2004). Diabetic cardiomyopathy: recent evidence from mouse models of type 1 and type 2 diabetes. Can J Physiol Pharmacol 82: 813-823.
52. + currents in type 1 and type 2 diabetes. J Physiol 537: 83-92.
53. Shimoni Y, Hunt D, Chuang M, Chen KY, Kargacin G, Severson D (2005). Modulation of potassium currents by angiotensin and oxidative stress in cardiac cells from the diabetic rat. J Physiol 567: 177-190.
54. + currents in diabetic rat cardiac myocytes. J Physiol 550: 401-412.
55. + currents by angiotensin and endothelin. Am J Physiol 284: H1168-H1181.
56. + current modulation in diabetic rats. Am J Physiol 287: H311-H319.
57. Silvestre JS, Heymes C, Oubenaissa A, Robert V, Aupetit-Faisant B, Carayon A et al. (1999). Activation of cardiac aldosterone production in rat myocardial infarction. Circulation 99: 2694-2701.
58. Silvestre JS, Robert V, Heymes C, Aupetit-Faisant B, Mouas C, Moalic JM et al. (1998). Myocardial production of aldosterone and corticosterone in the rat. Physiological regulation. J Biol Chem 273: 4883-4891.
59. Slight SH, Joseph J, Ganjam VK, Weber KT (1999). Extra-adrenal mineralocorticoids and cardiovascular tissue. J Mol Cell Cardiol 31: 1175-1184.
60. Struthers AD (1999). Why does spironolactone improve mortality over and above an ACE inhibitor in chronic heart failure? Br J Clin Pharmacol 47: 479-482.
61. Struthers AD (2004). Aldosterone in heart failure: pathophysiology and treatment. Curr Heart Fail Rep 1: 171-175.
62. Sun Y, Zhang J, Lu L, Chen SS, Quinn MT, Weber KT (2002). Aldosterone-induced inflammation in the rat heart: role of oxidative stress. Am J Pathol 161: 1773-1781.
63. Tomlinson C, Gardiner SM, Hebden RA, Bennett T (1992). Functional consequences of streptozotocin-induced diabetes mellitus, with particular reference to the cardiovascular system. Pharmacol Rev 44: 103-179.
64. Ustundag B, Cay M, Naziroglu M, Dilsiz N, Crabbe MJC, Ilhan N (1999). The study of renin-angiotensin-aldosterone in experimental diabetes mellitus. Cell Biochem Funct 17: 193-198.
65. Wasywich CA, Webster MW, Richards AM, Stewart RA (2006). Coronary sinus and ascending aortic levels of aldosterone, angiotensin II, and B-type natriuretic peptide in patients with aortic stenosis and in patients with coronary heart disease. Am J Cardiol 97: 1068-1072.
66. Yee KM, Pringle SD, Struthers AD (2001). Circadian variation in the effects of aldosterone blockade on heart rate variability and QT dispersion in congestive heart failure. J Am Coll Cardiol 37: 1800-1807.
67. Young MJ, Clyne CD, Cole TJ, Funder JW (2001). Cardiac steroidogenesis in the normal and failing heart. J Clin Endocrinol Metab 86: 5121-5126.
68. to in epicardial and endocardial ventricular myocytes from the canine heart. Circ Res 86: 1062-1068.
69. 2 in angiotensin II-induced vascular hypertrophy. Hypertension 32: 488-495.
70. + current. Cell Physiol Biochem 19: 225-238.
71. Zimmet P, Alberti GK, Shaw J (2001). Global and societal implications of the diabetes epidemic. Nature 414: 782-787.